Market Trends of Global Aminoglycosides Industry
This section covers the major market trends shaping the Aminoglycosides Market according to our research experts:
The Gentamicin Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Gentamicin is used in the treatment of serious infections that are caused by bacteria, such as infections of the blood, lungs, bones, joints, skin, and urinary tract and meningitis (infection of the membranes that surround the brain and spinal cord). Gentamicin is the agent of choice for major bacterial infections.
Increased research and development in the field of Gentamycin related topics boost the market growth. For instance as per the article published in 2022 under the title 'Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review', in both adults and children older than one month, including critically ill patients, a conventional gentamicin beginning dose of 7 mg/kg based on total body weight (or on ABW in obese patients) appears to be the most effective method for increasing the probability of target attainment (PTA) after the initial administration.
In veterinary medicine, drugs such as Gentamicin and Amikacin find maximum usage. Gentamicin is indicated in sepsis, acute/chronic renal disease, diabetes, perinatal complications, labor or neonatal complications, and UTI/pyelonephritis.
According to a research article published in 2020 under the title 'Epidemiology of urological infections: a global burden', globally, urinary tract infections were among the most frequent infections in clinical practice. The high burden of urinary tract infections is expected to increase the use of Gentamicin over the forecast period. Moreover, gentamicin forms the first line of treatment for many diseases. The usage of Gentamicin is particularly high in developing regions where it is a cost-effective and efficacious drug for many infectious diseases.
Thus, the demand for Gentamicin is consistently growing for different bacterial-related diseases, with several players using it in combinations. Hence, the aforementioned factors are expected to drive the market over the forecast period.
North America is Expected to Hold a Major Market Share Over the Forecast Period
The major factors driving the aminoglycoside market growth in North America include the increasing incidence of bacterial infections, growing demand for early-phase diagnosis and treatment of infectious diseases, and support from the government in the prevention of infection.
According to a research study published in August 2020 titled 'Studies highlight the dynamic impact of COVID-19 on antibiotic use', more than 1,700 hospitalized COVID-19 patients were treated at 38 Michigan hospitals in the United States from March 13, 2020, to June 18, 2020, more than half received early antibiotic therapy, with antibiotic use as high as 84% in some hospitals, which showed a positive impact on the market growth. Increased healthcare expenditure in the studied region boosts market growth. For instance, according to the 2021 report from WHO, by 2022, USD 13 billion is likely to be needed annually for TB prevention, diagnosis, treatment, and care to achieve the global target agreed upon at the UN high-level meeting on TB in 2018. Increasing funding and government initiatives are expected to drive the demand for aminoglycosides in the prevention of infectious diseases. For instance, one of the health objectives of the United Nations Sustainable Development Goals is to end the tuberculosis (TB) epidemic by 2030.
As per the factors mentioned above, the North America market is expected to grow over the forecast period.
